Discover
dexamethasone sodium phosphate (AVM0703) / AVM BiotechnologySeattle AVM Biotechnology announces second IND for AVM0703: clinical trial permitted to treat COVID-19 and Influenza ARDS with its "supercharged" version of dexamethasone (PRNewswire) - Sep 16, 2020 - "AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients....This second study consists of two different ARDS patient populations: one with COVID-19-mediated moderate to severe ARDS and the other with Influenza-mediated severe ARDS."
